Quick Answer
CUMBERLAND PHARMACEUTICALS INC reported Operating Income of -$2.79 million for fiscal year 2025.
CUMBERLAND PHARMACEUTICALS INC Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$2.79M | +56.6% |
| 2024 | -$6.43M | +32.7% |
| 2023 | -$9.55M | -67.5% |
| 2022 | -$5.70M | +25.7% |
| 2021 | -$7.68M | -20.3% |
| 2020 | -$6.38M | +31.3% |
| 2019 | -$9.29M | +16.9% |
| 2018 | -$11.17M | -173.8% |
| 2017 | -$4.08M | -184.8% |
| 2016 | -$1.43M | -228.9% |
| 2015 | $1.11M | -68.8% |
| 2014 | $3.56M | +193.6% |
| 2013 | -$3.80M | -143.1% |
| 2012 | $8.82M | -10.5% |
| 2011 | $9.85M | +51.5% |
| 2010 | $6.50M | +12.6% |
| 2009 | $5.78M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.97M | -16.0% | -162.9% |
| June 30, 2025 | -$747.5K | +27.2% | -157.9% |
| March 31, 2025 | $1.29M | +169.1% | +176.2% |
| September 30, 2024 | -$1.69M | +9.2% | -65.0% |
| June 30, 2024 | -$1.03M | -4591.4% | +45.1% |
| March 31, 2024 | -$1.87M | -22.0% | -0.1% |
| September 30, 2023 | -$1.87M | -546.8% | -8265.7% |
| June 30, 2023 | $22.9K | +101.2% | +101.5% |
- CUMBERLAND PHARMACEUTICALS INC showed an increase of +56.6% in Operating Income compared to the prior fiscal year.
- Over the 2009–2025 period, CUMBERLAND PHARMACEUTICALS INC’s operating income has declined by 148.3% (from $5.78 million to -$2.79 million).
- The most recent figure is from CUMBERLAND PHARMACEUTICALS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: